Turn­ing Point tracks an im­pres­sive ORR rate in NSCLC — but shares skid low­er on sec­ond look

CHICA­GO — Fresh off of a $166 mil­lion IPO raise, Turn­ing Point Ther­a­peu­tics $TP­TX joined the open­ing-day fes­tiv­i­ties at AS­CO with an up­date on their lead drug re­potrec­tinib — which they plan to pitch for an ear­ly ap­proval for ROS1+ ad­vanced non-small cell lung can­cer.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER